Literature DB >> 33140134

Analysis of blood stream infections, antibiograms and clinical outcomes in haematological patients with febrile neutropenia: data from a tertiary care haematology institute in India.

Shouriyo Ghosh1, Mandira Chakraborty2, Sambit Samanta1, Nilanjan Sinha1, Sandeep Saha1, Arnab Chattopadhyay1, Siddhartha Sankar Roy1, Maitreyee Bhattacharyya3.   

Abstract

Timely administration of appropriate empirical antibiotics in febrile neutropenia is crucial for favourable patient outcomes. There are guidelines in place recommending such antibiotics. However, regional variations and local epidemiological data must be evaluated to tailor the antibiotics for best possible and rational use. In this study, we audited the clinical and microbiological data of febrile neutropenic episodes occurring at a tertiary care haematology institution. Three hundred and ninety-three febrile neutropenic episodes occurring in 123 patients over a 1-year period were analysed for microbial profile, sensitivity and resistance patterns, and finally clinical outcomes. Gram-negative bacilli (GNB) blood stream infections (46.9%) were more prevalent as compared to gram-positive infections (41.9%). Overall mortality due to complicated neutropenic sepsis was 19.5% (24/123 patients). Increased resistance to carbapenems, beta-lactam beta-lactamase inhibitor combinations, aminoglycosides, fluoroquinolones, and cephalosporins were observed. Cefepime and tigecycline resistance were seen in 20% and 15% GNB isolates, respectively. Chest was the most frequent focus of infection, and acute myeloid leukaemia (AML) was the most common underlying disorder which correlated with the likelihood of death (p < 0.01). Multidrug-resistant GNB (esp. Klebsiella sp.) are still most worrisome isolates in neutropenic patients. Single-agent cefepime or piperacillin-tazobactam/tigecycline combination may be considered empirical agents. Chest infections and AML were independent predictors of poor clinical outcome in neutropenic patients. Regular audit of infections and antibiotic susceptibility data is needed to improve clinical outcomes in patients with febrile neutropenia.

Entities:  

Keywords:  Antibiograms; Clinical outcome; Empirical antibiotics; Febrile neutropenia; Predictors of severity of infection

Year:  2020        PMID: 33140134     DOI: 10.1007/s00277-020-04324-8

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  21 in total

1.  Epidemiology of antimicrobial resistance in an oncology center in eastern India.

Authors:  Sanjay Bhattacharya; Gaurav Goel; Sukdev Mukherjee; Jaydip Bhaumik; Mammen Chandy
Journal:  Infect Control Hosp Epidemiol       Date:  2015-04-22       Impact factor: 3.254

Review 2.  Shock and Early Death in Hematologic Patients with Febrile Neutropenia.

Authors:  Mariana Guarana; Marcio Nucci; Simone A Nouér
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

3.  Colistin-resistant Klebsiella pneumoniae: report of a cluster of 24 cases from a new oncology center in eastern India.

Authors:  Gaurav Goel; Lalawmpuia Hmar; Maitrayee Sarkar De; Sanjay Bhattacharya; Mammen Chandy
Journal:  Infect Control Hosp Epidemiol       Date:  2014-08       Impact factor: 3.254

4.  Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia.

Authors:  Kenneth V I Rolston
Journal:  Clin Infect Dis       Date:  2005-04-01       Impact factor: 9.079

5.  Treatment of patients with hematologic neoplasm, fever, and neutropenia.

Authors:  Kent A Sepkowitz
Journal:  Clin Infect Dis       Date:  2005-04-01       Impact factor: 9.079

6.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

7.  Micro-organisms Associated with Febrile Neutropenia in Patients with Haematological Malignancies in a Tertiary Care Hospital in Eastern India.

Authors:  Prakas Kumar Mandal; Suman Kumar Maji; Tuphan Kanti Dolai; Rajib De; Shyamali Dutta; Sandeep Saha; Maitreyee Bhattacharyya
Journal:  Indian J Hematol Blood Transfus       Date:  2014-05-04       Impact factor: 0.900

8.  Epidemiology of carbapenem-resistant Enterobacteriaceae: a 5-year experience at a tertiary care hospital.

Authors:  Darunee Chotiprasitsakul; Sirawat Srichatrapimuk; Suppachok Kirdlarp; Alexander D Pyden; Pitak Santanirand
Journal:  Infect Drug Resist       Date:  2019-02-20       Impact factor: 4.003

9.  Febrile Neutropenia in Hematological Malignancies: Clinical and Microbiological Profile and Outcome in High Risk Patients.

Authors:  Kuntegowdanahalli C Lakshmaiah; Abhayakumar S Malabagi; Rachan Shetty; Mahua Sinha; Rudrapatna S Jayashree
Journal:  J Lab Physicians       Date:  2015 Jul-Dec

10.  Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias.

Authors:  Alessandra Micozzi; Giuseppe Gentile; Clara Minotti; Claudio Cartoni; Saveria Capria; Daniele Ballarò; Stefania Santilli; Emanuele Pacetti; Sara Grammatico; Giampaolo Bucaneve; Robin Foà
Journal:  BMC Infect Dis       Date:  2017-03-10       Impact factor: 3.090

View more
  1 in total

1.  The clinical profile, management, and outcome of febrile neutropenia in acute myeloid leukemia from resource constraint settings.

Authors:  Kundan Mishra; Suman Kumar; Sandeep Ninawe; Rajat Bahl; Ashok Meshram; Kanwaljeet Singh; Aditya Jandial; Kamal Kant Sahu; Rajeev Sandal; Sanjeev Khera; Uday Yanamandra; Harshit Khurana; Rajiv Kumar; Rajan Kapoor; Sanjeevan Sharma; Jasjit Singh; Satyaranjan Das; Ankur Ahuja; Venkateshan Somasundaram; Tathagat Chaterjee
Journal:  Ther Adv Infect Dis       Date:  2021-08-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.